Real-world experience with circulating tumor DNA in cerebrospinal fluid from patients with central nervous system tumors

Central Nervous System Tumors

Do you want to read an article? Please log in or register.

RECOMMENDED

Reference

Hickman RA, Miller AM, Holle BM, Jee J, Liu SY, Ross D, Yu H, Riely GJ, Ombres C, Gewirtz AN, Reiner AS, Nandakumar S, Price A, Kaley TJ, Graham MS, Vanderbilt C, Rana S, Hill K, Chabot K, Campos C, Nafa K, Shukla N, Karajannis M, Li B, Berger M, Ladanyi M, Pentsova E, Boire A, Brannon AR, Bale T, Mellinghoff IK, Arcila ME

Acta Neuropathol Commun.
2024 Sep 17;12(1):151.
doi: 10.1186/s40478-024-01846-4.

Visit the full text of the original publication at actaneurocomms.biomedcentral.com

Reference

Related content

Rapid Tumor DNA Analysis of Cerebrospinal Fluid Accelerates Treatment of Central Nervous System Lymphoma

Central nervous system multiple myeloma: A real-world multi-institutional study of the Greek Myeloma Study Group

Liso-cel is effective and safe in a broad real-world population of R/R LBCLa patients, including second-line setting and secondary CNS involvement

Clinical characteristics and outcome of central nervous system tumors harboring NTRK gene fusions

Circulating Tumor DNA Sequencing for Biologic Classification and Individualized Risk Stratification in Patients With Hodgkin Lymphoma

Results of TRODELVY® real-world data

Gut microbiome modulates the outcome in primary central nervous system lymphoma patients undergoing chemotherapy: an ancillary study from the BLOCAGE trial

Considerations to forgo systemic treatment in patients with advanced esophageal or gastric cancer: A real-world evidence study

Comprehensive Genome Profiling for Treatment Decisions in Patients with Metastatic Tumors: Real-World Evidence Meta-Analysis and Registry Data Implementation

Liso-cel is effective and safe in a broad real-world population of R/R LBCL^a patients, including second-line setting and secondary CNS involvement

Results of TRODELVY^® real-world data